Immunoprecise Antibodies Ltd expected to post a loss of 8 cents a share - Earnings Preview

Mindwalk Holdings

26/03/2025 12:32

Immunoprecise Antibodies Ltd IPA.OQ IPA.O is expected to show a rise in quarterly revenue when it reports  results on March 28 for the period ending January 31 2025

The Victoria British Columbia-based  company is expected to report a 5.9% increase in revenue to C$6.585 million from C$6.22 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Immunoprecise Antibodies Ltd is for a loss of 8 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $4.79​, above​ its last closing price of $0.44. ​​​

This summary was machine generated March 26 at 12:32 GMT.  All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)